Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.
Adherence to first-line diabetes medication, ascertained from prescription records, is the only routine clinical variable that is a strong indicator of people’s adherence to second-line treatment, say researchers.
Short-term structured strength and balance training does not improve quality of life in patients with type 2 diabetes-related peripheral neuropathy, but may increase functional status and balance confidence, research shows.
Findings from a systematic review and meta-analysis suggest that SGLT2 inhibitors reduce the risk for major adverse kidney outcomes among people with type 2 diabetes, regardless of baseline kidney function.
Researchers have developed a novel clinical risk score for hospitalization for heart failure, which identifies people with type 2 diabetes most likely to benefit from sodium-glucose cotransporter 2 inhibition.
People with type 2 diabetes and obesity who undergo metabolic surgery have a significantly lower risk for major adverse cardiovascular events than those who do not receive surgery, observational study data show.
Findings from the THEMIS trial suggest that the addition of ticagrelor to aspirin treatment reduces the incidence of ischemic cardiovascular events among people with type 2 diabetes and stable coronary artery disease, but at the cost of an increased risk for major bleeding, resulting in an unfavorable risk:benefit ratio.
The effectiveness of interventions to increase objectively measured physical activity in people at high risk for developing type 2 diabetes declines in line with symptoms of depression within the normal range, say researchers.